

Remarks:


The specification has been amended to add a priority claim to the corresponding national phase application. Accordingly, no new matter has been added by this amendment.

Claims 1-45 are subject to examination. Claims 3-14, 20, 26-31, and 33-44 have been amended to remove multiple dependencies and to recite the phrase “a pharmaceutically acceptable salt, ester, or prodrug thereof,” where missing. Support for the amendments can be found at least in claim 1 as filed. No new matter has been added by these amendments.

Although no additional charges are believed to be due, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 26505-525 NATL. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: January 27, 2006



Ivor R. Elrifi, Reg. No. 39529
Heidi A. Erlacher, Reg. No. 45,409
Attorneys for Applicant
MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, MA 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Customer No. 30623